RLMD
Relmada Therapeutics Inc

2,165
Mkt Cap
$636.68M
Volume
1.57M
52W High
$7.51
52W Low
$0.243
PE Ratio
-4.13
RLMD Fundamentals
Price
$6.07
Prev Close
$6.25
Open
$6.50
50D MA
$4.53
Beta
0.48
Avg. Volume
653,706.18
EPS (Annual)
-$1.45
P/B
5.15
Rev/Employee
$0.00
$97.68
Loading...
Loading...
News
all
press releases
Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00
Mizuho raised their target price on Relmada Therapeutics from $10.00 to $19.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat.com reports...
MarketBeat·2d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results, Misses Estimates By $0.15 EPS
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) posted its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.15...
MarketBeat·2d ago
News Placeholder
Relmada Therapeutics Q4 Earnings Call Highlights
Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting durable Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), plans to begin a Phase...
MarketBeat·2d ago
News Placeholder
Short Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Drops By 24.8%
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 836,254...
MarketBeat·8d ago
News Placeholder
Relmada Therapeutics (RLMD) Projected to Post Earnings on Thursday
Relmada Therapeutics (NASDAQ:RLMD) will be releasing its Q4 2025 earnings after the market closes on Thursday, March 19. (View Earnings Report at...
MarketBeat·9d ago
News Placeholder
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
Zacks·10d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap Down - Time to Sell?
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap Down - Here's Why...
MarketBeat·12d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month High - Should You Buy?
Relmada Therapeutics (NASDAQ:RLMD) Hits New 1-Year High - Still a Buy...
MarketBeat·12d ago
News Placeholder
Biotech Stocks To Add to Your Watchlist - March 9th
Moderna, Dianthus Therapeutics, Danaher, United Therapeutics, and Relmada Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...
MarketBeat·12d ago
<
1
2
...
>

Latest RLMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.